Nutrition-Gut-Brain Interactions Research Centre, Faculty of Medicine and Health, School of Medical Sciences, Örebro University, Örebro, Sweden.
Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, Örebro University Hospital, Örebro, Sweden.
Scand J Gastroenterol. 2020 Dec;55(12):1454-1466. doi: 10.1080/00365521.2020.1839544. Epub 2020 Nov 3.
Faecal microbiota transfer (FMT) consists of the infusion of donor faecal material into the intestine of patients with the aim to restore a disturbed gut microbiota.
In this pilot study (NCT03275467), the effect of three repeated FMTs (day 0, two weeks, four weeks) was studied and followed up for six months in nine collagenous colitis (CC) patients, using two stool donors.
Five patients had an active disease at the time of baseline sampling. The primary endpoint (remission at six weeks, defined as <3 stools whereof <1 watery stool per day) was achieved by two of these patients, and by one at eight weeks. Overall, in all nine patients, FMT did not result in a significant reduction of watery stools, assessed by daily diary. However, diarrhoea (assessed by gastrointestinal symptom rating scale) was significantly improved at four ( = .038) and eight weeks ( = .038), indigestion at eight ( = .045) and 12 weeks ( = .006), disease-related worries at four ( = .027) and eight weeks ( = .027), and quality of life at six months ( = .009). FMT resulted in an increased number of lamina propria lymphocytes, possibly indicating an initial mucosal immune activation. No serious adverse events, no systemic effects, and no changes in faecal calprotectin and psychological symptoms were observed.
FMT is able to improve symptoms in a yet undefined subset of CC patients. Further studies could help to characterise this subset and to understand if these results can be generalised to all microscopic colitis patients.
粪便微生物群转移(FMT)包括将供体粪便物质输注到患者的肠道中,以恢复肠道微生物群的紊乱。
在这项初步研究(NCT03275467)中,对 9 例胶原性结肠炎(CC)患者进行了三次重复 FMT(第 0 天、两周、四周)的研究,并随访了六个月,使用了两名粪便供体。
5 名患者在基线采样时患有活动期疾病。两名患者达到了主要终点(6 周缓解,定义为<3 次大便,<1 次稀便/天),一名患者在 8 周时达到了缓解。总体而言,在所有 9 名患者中,FMT 并未显著减少水样便,通过每日日记评估。然而,通过胃肠道症状评分量表评估,腹泻在四周( = .038)和八周( = .038)、消化不良在八周( = .045)和十二周( = .006)、疾病相关担忧在四周( = .027)和八周( = .027)以及六个月时的生活质量( = .009)均得到显著改善。FMT 导致固有层淋巴细胞数量增加,可能表明初始黏膜免疫激活。未观察到严重不良事件、全身效应以及粪便钙卫蛋白和心理症状的变化。
FMT 能够改善 CC 患者中尚未明确的亚组的症状。进一步的研究可以帮助确定这一亚组,并了解这些结果是否可以推广到所有显微镜下结肠炎患者。